There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on T2 Biosystems (TTOO) and Aurinia Pharmaceuticals (AUPH) with bullish sentiments.
T2 Biosystems (TTOO)
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on T2 Biosystems, with a price target of $3.50. The company’s shares closed last Friday at $1.19.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 44.2% and a 43.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Adaptimmune Therapeutics.
T2 Biosystems has an analyst consensus of Strong Buy, with a price target consensus of $2.91, which is a 129.1% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $3.50 price target.
See today’s analyst top recommended stocks >>
Aurinia Pharmaceuticals (AUPH)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals today and set a price target of $35.00. The company’s shares closed last Friday at $10.17.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 13.6% and a 38.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Paratek Pharmaceuticals, and Galmed Pharmaceuticals.
Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $27.40, a 156.6% upside from current levels. In a report issued on April 26, Leerink Partners also maintained a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
